von Moltke Lisa 4

What Happened
Lisa von Moltke, Head of Research & Development and Chief Medical Officer of Zenas BioPharma (ZBIO), was granted a derivative award covering 150,000 shares on June 15, 2026. The grant is reported as an acquisition (Code A) with a reported price of $0.00 per share (derivative).

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-17 (filed timely).
• Amount: 150,000 derivative securities granted; reported price $0.00.
• Vesting: 25% vests on June 15, 2027 (one-year cliff), remainder vests in equal monthly installments over the following 36 months, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the filing.
• Notes: Footnote explicitly describes this as an option-style vesting schedule; filing shows an award/grant rather than a purchase or sale.

Context
This was a grants/award transaction (not a market purchase or sale). For retail investors, grants indicate compensation and potential future dilution as options vest and are exercised; they do not by themselves signal immediate buying or selling of stock.